

AVX 13616

Catalog No: tcsc3189



Available Sizes

Size: 5mg

Size: 10mg

Size: 50mg

Size: 100mg



Specifications

CAS No:

900814-48-4

Formula:

$C_{50}H_{73}Cl_2N_7O_7$

Pathway:

Anti-infection

Target:

Bacterial

Purity / Grade:

>98%

Solubility:

10 mM in DMSO

Observed Molecular Weight:

955.06

Product Description


AVX 13616 shows the potent in vivo antibacterial activity of Avexa's lead antibacterial candidate; particularly against drug-resistant

Staphylococcus pathogens.

IC50 value: 2-4 ug/ml (MICs)

Target: antibacterial agent

AVX13616 was as active as mupirocin in a nasal decolonization model but required only a single application. The compounds are being developed for topical indications and/or wound infection/catheter-related infections. AVX13616 and other compounds showed broad spectrum antibacterial activity against a range of isolates with MICs of 2-4 micrograms per millilitre against *S. aureus*, coagulase negative staphylococci, enterococci, MRSA, VISA and VRSA. A single application of 5% (w/w) AVX13616 (approximately equimolar to 2% mupirocin) was as effective as 2% mupirocin administered twice a day for five days in nasal decolonisation of MRSA in mice.



All products are for RESEARCH USE ONLY. Not for diagnostic & therapeutic purposes!